论文部分内容阅读
20余年来,由于烷化剂的应用及支持疗法的改进。多发性骨髓瘤(MM)患者的中数生存期由以往的6～12个月延长为2～3年,少数患者可生存10年或更长,且生存质量也得到改善。现将本病的治疗近况概述如下。多发性骨髓瘤的治疗原则是合理联合抗癌药物
For more than 20 years, due to the use of alkylating agents and improvements in supportive therapies. The median survival in patients with multiple myeloma (MM) has been extended from 2 to 3 years from 6 to 12 months in the past, with a minority of patients surviving for 10 years or more and quality of life improved. Now the treatment of the disease is summarized as follows. The principle of treatment of multiple myeloma is a reasonable combination of anti-cancer drugs